-
1
-
-
33746681908
-
ATP-sensitive potassium channels-neonatal diabetes mellitus and beyond
-
Sperling M.A. ATP-sensitive potassium channels-neonatal diabetes mellitus and beyond. N Engl J Med. 355 (2006) 507-510
-
(2006)
N Engl J Med.
, vol.355
, pp. 507-510
-
-
Sperling, M.A.1
-
2
-
-
23344439106
-
Neonatal diabetes mellitus: From understudy to center stage
-
Sperling M.A. Neonatal diabetes mellitus: From understudy to center stage. Curr Opin Pediatr. 17 (2005) 512-518
-
(2005)
Curr Opin Pediatr.
, vol.17
, pp. 512-518
-
-
Sperling, M.A.1
-
3
-
-
33846851524
-
The genetic basis of neonatal diabetes mellitus
-
Sperling M.A. The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev. 4 Suppl 1 (2006) 71-75
-
(2006)
Pediatr Endocrinol Rev.
, vol.4
, Issue.SUPPL. 1
, pp. 71-75
-
-
Sperling, M.A.1
-
4
-
-
4644260056
-
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy
-
Sagen J.V., Raeder H., Hathout E., et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes. 53 (2004) 2713-2718
-
(2004)
Diabetes.
, vol.53
, pp. 2713-2718
-
-
Sagen, J.V.1
Raeder, H.2
Hathout, E.3
-
5
-
-
8744262895
-
Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
-
Zung A., Glaser B., Nimri R., and Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 89 (2004) 5504-5507
-
(2004)
J Clin Endocrinol Metab.
, vol.89
, pp. 5504-5507
-
-
Zung, A.1
Glaser, B.2
Nimri, R.3
Zadik, Z.4
-
6
-
-
24144467758
-
Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy
-
Hattersley A.T., and Ashcroft F.M. Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes. 54 (2005) 2503-2513
-
(2005)
Diabetes.
, vol.54
, pp. 2503-2513
-
-
Hattersley, A.T.1
Ashcroft, F.M.2
-
7
-
-
14644408737
-
High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation
-
Codner E., Flanagan S., Ellard S., et al. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care. 28 (2005) 758-759
-
(2005)
Diabetes Care.
, vol.28
, pp. 758-759
-
-
Codner, E.1
Flanagan, S.2
Ellard, S.3
-
8
-
-
33746686369
-
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
-
the Neonatal Diabetes International Collaborative Group
-
Pearson E.R., Flechtner I., Njølstad P.R., et al., the Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 355 (2006) 467-477
-
(2006)
N Engl J Med.
, vol.355
, pp. 467-477
-
-
Pearson, E.R.1
Flechtner, I.2
Njølstad, P.R.3
-
9
-
-
34147167267
-
Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers
-
Stanik J., Gasperikova D., Paskova M., et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab. 92 (2007) 1276-1282
-
(2007)
J Clin Endocrinol Metab.
, vol.92
, pp. 1276-1282
-
-
Stanik, J.1
Gasperikova, D.2
Paskova, M.3
-
10
-
-
34247562272
-
Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days
-
Codner E., Flanagan S.E., Ugarte F., et al. Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care. 30 (2007) e28-e29
-
(2007)
Diabetes Care.
, vol.30
-
-
Codner, E.1
Flanagan, S.E.2
Ugarte, F.3
-
11
-
-
44649180550
-
Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide
-
Bremer A.A., Ranadive S., and Lustig R.H. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide. Pediatr Diabetes. 9 (2008) 236-239
-
(2008)
Pediatr Diabetes.
, vol.9
, pp. 236-239
-
-
Bremer, A.A.1
Ranadive, S.2
Lustig, R.H.3
-
12
-
-
52649099443
-
Diagnosis and treatment of neonatal diabetes: A United States experience
-
the United States Neonatal Diabetes Working Group
-
Støy J., Greeley S.A., Paz V.P., et al., the United States Neonatal Diabetes Working Group. Diagnosis and treatment of neonatal diabetes: A United States experience. Pediatr Diabetes. 9 (2008) 450-459
-
(2008)
Pediatr Diabetes.
, vol.9
, pp. 450-459
-
-
Støy, J.1
Greeley, S.A.2
Paz, V.P.3
-
13
-
-
0018356027
-
Transient neonatal diabetes mellitus. Treatment with chlorpropamide
-
Kuna P., and Addy D.P. Transient neonatal diabetes mellitus. Treatment with chlorpropamide. Am J Dis Child. 133 (1979) 65-66
-
(1979)
Am J Dis Child.
, vol.133
, pp. 65-66
-
-
Kuna, P.1
Addy, D.P.2
-
14
-
-
47649125429
-
Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: Initial response to oral sulphonylurea therapy
-
Turkkahraman D., Bircan I., Tribble N.D., et al. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: Initial response to oral sulphonylurea therapy. J Pediatr. 153 (2008) 122-126
-
(2008)
J Pediatr.
, vol.153
, pp. 122-126
-
-
Turkkahraman, D.1
Bircan, I.2
Tribble, N.D.3
-
15
-
-
23644442552
-
ATP-sensitive potassium: Focus on insulin secretion
-
Ashcroft F.M. ATP-sensitive potassium: Focus on insulin secretion. J Clin Invest. 115 (2005) 2047-2058
-
(2005)
J Clin Invest.
, vol.115
, pp. 2047-2058
-
-
Ashcroft, F.M.1
|